Miwa L J, Edmunds A L, Shaefer M S, Raynor S C
Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha.
DICP. 1989 Oct;23(10):773-5. doi: 10.1177/106002808902301006.
Oral contraceptives are one of the most effective and widely used of the reversible contraceptive methods. Thromboembolic disease associated with the use of oral contraceptives has been widely reported. In recent years, attempts to understand the pathogenesis of oral contraceptive-induced thromboembolic disease have found a correlation between larger estrogen doses and increased risk for a thrombotic event. Because the newer triphasic oral contraceptives provide effective contraception with a method of administration that mimics normal hormonal fluctuations during the menstrual cycle, some prescribers may infer that these products are associated with a decreased incidence of adverse effects over alternative oral contraceptives. We present two cases of idiopathic thromboembolism associated with the use of a triphasic oral contraceptive with a discussion of the proposed pathogenic mechanisms for these events.
口服避孕药是最有效且使用最广泛的可逆避孕方法之一。与口服避孕药使用相关的血栓栓塞性疾病已被广泛报道。近年来，为了解口服避孕药所致血栓栓塞性疾病的发病机制所做的尝试发现，较大剂量雌激素与血栓形成事件风险增加之间存在关联。由于新型三相口服避孕药通过一种模拟月经周期中正常激素波动的给药方法提供有效的避孕效果，一些开处方者可能会推断，与其他口服避孕药相比，这些产品的不良反应发生率更低。我们报告两例与使用三相口服避孕药相关的特发性血栓栓塞病例，并讨论这些事件的潜在致病机制。
